← Back to patent-cliff list
nL-ATN1-001
Tier C — Watch / tradenL-ATN1-001
N-Lorem Foundation
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：ATN1
Indications (approved)：Atrophy
Regional status
US
Phase II
2025-11-06
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of nL-ATN1-001?
Approved indications include: Atrophy.
When does the nL-ATN1-001 patent expire?
No public expiry year is available for nL-ATN1-001 yet; this page updates once verified.
How do I get a quote for nL-ATN1-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30